Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TGI-6 in advanced solid tumors
NCT06374173Phase 1Recruiting
- Sponsor
- Hefei TG ImmunoPharma Co., Ltd.
- Start
- Jan 2024
- Primary completion
- Sep 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TGI-6 in solid tumor and colorectal cancer (CRC), sponsored by Hefei TG ImmunoPharma Co., Ltd. Primary endpoints: Dose-limiting Toxicity, Dose-Finding and 1 more. Started Jan 2024; status: recruiting.
02
Drugs
TGI-6
03
Conditions
solid tumorcolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06374173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06374173.